Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination
- 1 December 2014
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 196, 122-131
Abstract
No abstract availableKeywords
Funding Information
- Portuguese Foundation for Science and Technology (FCT) (SFRH/BD/64243/2009)
- InovC/UC (2013)
- Sistemas de Bolsas de Ignição do Programa Estratégico Inov C financiado pelo QREN, no âmbito do Mais Centro - Programa Operacional Regional do Centro, QREN/FEDER/COMPETE (30248/IN0617)
This publication has 52 references indexed in Scilit:
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast CancerThe Oncologist, 2011
- Use of nanoscale delivery systems to maintain synergistic drug ratiosin vivoExpert Opinion on Drug Delivery, 2010
- Ceramide Produces Apoptosis Through Induction of p27kip1by Protein Phosphatase 2A-dependent Akt Dephosphorylation in PC-3 Prostate Cancer CellsJournal of Toxicology and Environmental Health, Part A, 2010
- The PI3K Pathway As Drug Target in Human CancerJournal of Clinical Oncology, 2010
- Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and β-catenin signalingMolecular Cancer, 2010
- Ceramide induces p38 MAPK-dependent apoptosis and Bax translocation via inhibition of Akt in HL-60 cellsCancer Letters, 2008
- Rational Design of Cancer-Drug CombinationsNew England Journal of Medicine, 2007
- Drug resistance in chemotherapy for breast cancerCancer Chemotherapy and Pharmacology, 2005